|
|
|
14.11.25 - 17:42
|
Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy (Benzinga)
|
|
|
Bristol Myers and Johnson & Johnson ended the Librexia ACS trial after an interim review showed low efficacy, while AF and stroke studies continue with data expected in 2026.
Latest Ratings for BMY
DateFirmActionFromTo Mar 2022Wells FargoMaintainsEqual-Weight Dec 2021Goldman SachsInitiates Coverage OnBuy Dec 2021Wells FargoInitiates Coverage OnEqual-Weight
View More Analyst Ratings for BMY
View the Latest Analyst Ratings
read more...
|
|
|
|
|
|
|
|
|
|
|
|
|
10.11.25 - 07:33
|
Almirall′s 2025 9M Results (Business Wire)
|
|
|
Almirall continues its sustained growth trajectory in 9M 2025 - delivering 12.8% net sales growth, strong dermatology performance, solid commercial execution in Europe, and further pipeline progress
Sustained strong growth momentum with 12.8% Net Sales YoY increase to a total of €820.7 MM, with biologics continuing to deliver double-digit growth YoY and dermatology sales in Europe increasing 24.5% YoY further advancing Almirall´s leadership in medical dermatology.
EBITDA increase of 27.1% YoY in line with expectations, reaching a total of €180.7 MM. On track to meet 2025 guidance driven by biologics growth and operational strength.
Performance continues to be primarily driven by the biologics portfolio, with Ilumetri® net sales increasing 12.1% YoY (total of €170.9 MM), and Ebglyss® net sales of €75.5 MM – reflecting a more than 3x increase YoY as European markets are ramping up after launch.
Solid performance of the broad dermatology product portfolio with Wynzora® growing 32.4% YoY to a to...
|
|
|
|
|
|
|
|
|
|
|
04.11.25 - 19:18
|
Grifols 9-Month Profit Rises 245% (AFX)
|
|
|
MADRID (dpa-AFX) - Healthcare company Grifols (GRFS) on Tuesday reported a net profit of 304 million euros for the first nine months, up 245% compared to 88 million euros for the same period of 20......
|
|
|
03.11.25 - 14:03
|
ORYZON Announces First‑Patient‑In (FPI) in RESTORE Phase Ib Trial of Iadademstat in Sickle Cell Disease (GlobeNewswire EN)
|
|
|
MADRID and CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical‑stage biopharmaceutical company and global leader in epigenetics, today announced that the first patient has been enrolled in RESTORE, its multi‑center, open‑label Phase Ib clinical trial of iadademstat in adults with sickle cell disease (SCD). The study, to be conducted across several sites in Spain, aims to enroll approximately 40 adult patients. It is designed to evaluate the safety and tolerability of iadademstat in SCD and to establish the recommended Phase 2 dose (RP2D) as well as to evaluate iadademstat's effect on inducing fetal hemoglobin (HbF) expression. Increases in HbF have already been recognized by the FDA as a clinically meaningful endpoint for the treatment of SCD....
|
|
|
30.10.25 - 13:03
|
ORYZON to Participate in Upcoming Events in November (GlobeNewswire EN)
|
|
|
MADRID, Spain and CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events:...
|
|
|
|
|
17.10.25 - 18:12
|
ORYZON Receives Feedback From the FDA in Response to the Submitted Phase III Protocol in Borderline Personality Disorder (GlobeNewswire EN)
|
|
|
MADRID, Spain and CAMBRIDGE, Mass., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, BME: ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that it has received written feedback from the U.S. Food and Drug Administration (FDA) regarding the Phase III protocol to evaluate vafidemstat in borderline personality disorder (BPD). The FDA's guidance covers different elements such as the selection of study endpoints and certain non-clinical considerations. Oryzon will incorporate these insights and resubmit the revised Phase III protocol. The company underlines that such iterative interactions are common in regulatory dialogue....
|
|
|
09.10.25 - 09:54
|
Madrid Hospitals Overwhelmed By Illegals As Spaniards Endure Longer Healthcare Waits (ZeroHedge)
|
|
|
Madrid Hospitals Overwhelmed By Illegals As Spaniards Endure Longer Healthcare Waits
Authored by Thomas Brooke via Remix News,
Spain's public healthcare system is treating a growing number of undocumented migrants and displaced foreigners, despite Spaniards enduring increasingly longer waiting times for appointments and operations.
Figures released by Madrid's Ministry of Health show that the Spanish capital alone has registered a 44 percent jump in patients without residency papers in the last year, while the Canary Islands have agreed to take in sick and wounded minors from Gaza at the request of the central government, despite its own residents having to wait an average of 122 days for surgery appointments.
According to data published by El Confidencial, the Madrid Health Service (Sermas) provided medical care to 190,000 people in an irregular situation over the past year, compared with 134,000 the year before. The figure represents an increase of 60,000 patients in 12 months, as the reg...
|
|
|
01.10.25 - 15:06
|
Predicta Biosciences Secures $23.4M to Scale its Novel Diagnostic and Analytics Platform for Blood Cancers and Autoimmune Diseases (Business Wire)
|
|
|
Brian McKernan joins as CEO to further advance Predicta's clinical impact, including its non-invasive diagnostic for Multiple MyelomaCAMBRIDGE, Mass.--(BUSINESS WIRE)--Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, today announced it has raised an oversubscribed $23.4 million Series A led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute and Myeloma Solutions Fund. The capital will be used to expand Predicta's team and CLIA-approved lab infrastructure, and advance commercialization of the company's first test, GenoPredicta and further development of other non-invasive diagnostic solutions for blood cancers and autoimmune diseases. In addition to the successful raise, Predicta also announced the appointment of Brian McKernan as CEO.
“It's an honor to join Predicta and our strong tea...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
